Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
MarketBeat

Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect

Climb Bio (NASDAQ:CLYM) outlined its clinical development strategy and upcoming data readouts during a fireside chat at H.C. Wainwright’s BioConnect Conference, with management emphasizing two biologic drug programs aimed at immune-mediated diseases, including nephrology and hematology indications.

H.C. Wainwright analyst Ram Selvaraju, who hosted the discussion, said his firm covers Climb Bio with a buy rating and a 12-month price target of $20 per share. Susan Altschuller, chief financial officer of Climb Bio, and Perrin Wilson, chief business officer, represented the company at the event.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.